Home > Haematology > EHA 2019 > Lymphoid Malignancies > CAR-T cell therapy in ALL as breakthrough advance

CAR-T cell therapy in ALL as breakthrough advance

Expert
Prof. Mohamad Mohty, Saint-Antoine Hospital and University Pierre & Marie Curie, France
Conference
EHA 2019
Trial
Phase 2, ELIANA

Prof. Mohamad Mohty (Saint-Antoine Hospital and University Pierre & Marie Curie, France) gave a state-of-the-art lecture about the recent advances and challenges in chimeric antigen receptors T cell (CAR-T) therapy in acute lymphocytic leukaemia (ALL) [1].

The key take-home messages were (1) if minimal residual disease (MRD) negativity is achieved after CAR-T cell therapy, the majority of patients will be cured; (2) allogenic transplantation after CAR-T cell therapy grants patients an even better survival; (3) success of CAR-T cell therapy seems to be mostly dependent on the post-infusion expansion of CAR-T cells; and (4) the challenges, such as cytokine release syndrome (CRS) or CD19-negative relapse, require internationally coordinated homogeneous criteria.

The pivotal single-arm phase 2 ELIANA study infused 63 heavily pre-treated patients (half had had one or more stem cell transpl...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on